Literature DB >> 8060375

Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men.

M Cigolini1, G Targher, J C Seidell, R Schiavon, F Manara, M G Zenti, C Mattioli, G De Sandre.   

Abstract

Increased plasma levels of plasminogen activator inhibitor-1 (PAI-1), responsible for reduced fibrinolytic activity, have been shown to be an important risk factor for cardiovascular disease. PAI-1 plasma levels are influenced by several factors which have not yet been fully clarified, including dietary fat intake. The relationships of PAI-1 with other cardiovascular risk factors are still not well known. In a random sample of 38-year-old healthy men (n = 94), the association of PAI-1 plasma levels (measured as activity and antigen) with anthropometric parameters, serum lipids, fasting and 2 h insulin and glucose concentration after oral glucose-load was analysed. Furthermore, the fatty acid composition of subcutaneous adipose tissue, as an objective and reliable index of dietary fat intake, was measured. The univariate analysis showed that plasma levels of PAI-1 were significantly associated with body mass index (BMI) (r = 0.37, P < 0.001), waist/hip ratio (WHR) (r = 0.26, P < 0.01), serum triglycerides (r = 0.47, P < 0.0001), HDL/total cholesterol ratio (r = -0.35, P < 0.001), fasting and 2-h insulin (r = 0.27, P < 0.01 and r = 0.34, P < 0.001) and glucose concentrations (r = 0.25, P < 0.05 and r = 0.28, P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8060375     DOI: 10.1016/0021-9150(94)90119-8

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Increased risk for cardiovascular outcomes and effect of cholesterol-lowering pravastatin therapy in patients with diabetes mellitus in the pravastatin anti-atherosclerosis trial in the elderly (PATE).

Authors:  Toshitsugu Ishikawa; Hideki Ito; Yasuyoshi Ouchi; Yasuo Ohashi; Yasushi Saito; Haruo Nakamura; Hajime Orimo
Journal:  Curr Ther Res Clin Exp       Date:  2005-01

Review 2.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

3.  Plasma fibrinogen, tissue plasminogen activator, plasminogen activator inhibitor 1, and their related factors in three Japanese population samples.

Authors:  K A Koike; H Iso; T Shimamoto; M Kudo; U Umemura; S Sato; Y Naito; M Iida; Y Komachi
Journal:  Environ Health Prev Med       Date:  1998-10       Impact factor: 3.674

4.  Prenylcysteine oxidase 1, an emerging player in atherosclerosis.

Authors:  C Banfi; R Baetta; S S Barbieri; M Brioschi; A Guarino; S Ghilardi; L Sandrini; S Eligini; G Polvani; O Bergman; P Eriksson; E Tremoli
Journal:  Commun Biol       Date:  2021-09-21

5.  The role of the platelet pool of Plasminogen Activator Inhibitor-1 in well-controlled type 2 diabetes patients.

Authors:  Karin Mossberg; Josefin Olausson; Emanuel Fryk; Sverker Jern; Per-Anders Jansson; Helén Brogren
Journal:  PLoS One       Date:  2022-08-31       Impact factor: 3.752

6.  Association of adipokines and adhesion molecules with indicators of obesity in women undergoing mammography screening.

Authors:  Caroline Isoppo de Souza; Daniela Dornelles Rosa; Betina Ettrich; Gabriela Hermann Cibeira; Juliana Giacomazzi; Paloma Tusset; Patrícia Ashton-Prolla; Lidia Rosi Medeiros; Maira Caleffi; Eurico Camargo Neto; Emilio Hideyuki Moriguchi; Marcia Silveira Graudenz
Journal:  Nutr Metab (Lond)       Date:  2012-10-31       Impact factor: 4.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.